| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | A1BG |
| Uniprot No | P04217-2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-373aa |
| 氨基酸序列 | MAPVSWITPGLKTTAVCRGVLRGVTFLLRREGDHEFLEVPEAQEDVEATF PVHQPGNYSCSYRTDGEGALSEPSATVTIEELAAPPPPVLMHHGESSQVL HPGNKVTLTCVAPLSGVDFQLRRGEKELLVPRSSTSPDRIFFHLNAVALG DGGHYTCRYRLH DNQNGWSGDSAPVELILSDETLPAPEFSPEPESGRA LRLRCLAPLEGARFALVREDRGGRRVHRFQSPAGTEALFELHNISVADSA NYSCVYVDLKPPFGGSAPSERL ELHVDGPPPRPQLRATWSGAVLAGRD AVLRCEGPIPDVTFELLREGETKAVKTVRTPGAAANLELIFVGPQHAGNY RCRYRSWVPHTFESELSDPVELLVAES |
| 预测分子量 | 67 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于A1BG重组蛋白的3篇示例参考文献(虚构内容，仅供格式参考)：
1. **标题**: "Expression and Characterization of Recombinant Human Alpha-1-B Glycoprotein (A1BG) in Mammalian Cells"
**作者**: Smith J, et al.
**摘要**: 本研究通过哺乳动物细胞表达系统成功克隆并纯化了重组A1BG蛋白，分析了其糖基化修饰特性及在血清中的潜在免疫调节功能。
2. **标题**: "A1BG as a Novel Regulator of Complement Activation: Insights from Recombinant Protein Studies"
**作者**: Zhang L, et al.
**摘要**: 利用重组A1BG蛋白进行功能实验，揭示了其通过结合补体C3蛋白抑制过度炎症反应的分子机制，为自身免疫疾病治疗提供新靶点。
3. **标题**: "Proteomic Analysis of A1BG Isoforms in Hepatocellular Carcinoma Using Recombinant Standards"
**作者**: Johnson R, et al.
**摘要**: 开发重组A1BG异构体作为质谱定量标准品，发现肝癌患者血清中A1BG的异常糖基化模式与肿瘤转移显著相关。
---
**注**：以上为模拟示例，实际文献请通过PubMed、Web of Science等学术数据库检索关键词"A1BG recombinant protein"或"Alpha-1-B glycoprotein expression"。
The A1BG (Alpha-1-B glycoprotein) recombinant protein is derived from the A1BG gene, which encodes a plasma glycoprotein predominantly synthesized in the liver. First identified in the 1970s, A1BG is a member of the immunoglobulin superfamily, characterized by its conserved structural domains and potential roles in immune regulation. Despite its discovery decades ago, the precise biological function of A1BG remains incompletely understood. Studies suggest its involvement in modulating immune responses, cell adhesion, and inflammation, though mechanistic details are still under investigation. Its expression is detected in various tissues, with elevated levels observed in certain pathological conditions, including cancers and autoimmune disorders, hinting at its possible role as a biomarker or therapeutic target.
Recombinant A1BG is produced using biotechnological methods, typically through expression systems like mammalian cells (e.g., CHO or HEK293) to ensure proper post-translational modifications, such as glycosylation, which may influence its stability and function. The purified protein is utilized in research to explore its interactions with other molecules, such as cytokines, extracellular matrix components, or cell surface receptors. Recent studies have linked A1BG to pathways involving TGF-β and complement systems, suggesting its regulatory effects on immune cell activity and tissue remodeling.
Interest in recombinant A1BG has grown due to its potential applications in diagnostics and therapeutics. For instance, altered A1BG levels in serum have been correlated with diseases like hepatocellular carcinoma and rheumatoid arthritis, underscoring its diagnostic utility. Additionally, its immunomodulatory properties are being explored in drug development, particularly for autoimmune and inflammatory conditions. However, further functional and structural studies are needed to clarify its exact mechanisms and harness its full biomedical potential. Overall, A1BG recombinant protein serves as a critical tool for unraveling the enigmatic roles of this glycoprotein in health and disease.
×
